<- Go Home
Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Market Cap
$530.3M
Volume
318.1K
Cash and Equivalents
$25.0M
EBITDA
-$78.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$35.3M
Profit Margin
59808.47%
52 Week High
$24.27
52 Week Low
$3.39
Dividend
N/A
Price / Book Value
7.16
Price / Earnings
-3.70
Price / Tangible Book Value
8.46
Enterprise Value
$448.3M
Enterprise Value / EBITDA
-5.71
Operating Income
-$79.2M
Return on Equity
88.76%
Return on Assets
-41.50
Cash and Short Term Investments
$82.0M
Debt
N/A
Equity
$68.3M
Revenue
$59.0K
Unlevered FCF
-$23.3M
Sector
Biotechnology
Category
N/A